Matteo Levisetti - 17 Jan 2023 Form 3 Insider Report for Cue Biopharma, Inc. (CUE)

Role
Chief Medical Officer
Signature
/s/ Matteo Levisetti by Colin Sandercock, attorney-in-fact
Issuer symbol
CUE
Transactions as of
17 Jan 2023
Transactions value $
$0
Form type
3
Filing time
19 Jan 2023, 15:01:42 UTC
Next filing
25 Jul 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding CUE Common Stock 9.23K 17 Jan 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding CUE Stock Option (right to buy) 17 Jan 2023 Common Stock 75K $13.14 Direct F1
holding CUE Stock Option (right to buy) 17 Jan 2023 Common Stock 43K $6.91 Direct F2
holding CUE Stock Option (right to buy) 17 Jan 2023 Common Stock 10K $5.01 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These stock options become exercisable in eight equal semi-annual installments beginning August 22, 2021.
F2 These stock options become exercisable in eight equal semi-annual installments beginning August 9, 2022.
F3 These stock options become exercisable in eight equal semi-annual installments beginning September 25, 2022.